A Harvard-led team is the first to demonstrate the ability to use low-power light to trigger stem cells inside the body to regenerate tissue, an advance they reported in Science Translational Medicine. The research, led by David J. Mooney, Robert P. Pinkas Family Professor of Bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS), lays the foundation for a host of clinical applications in restorative dentistry and regenerative medicine more broadly, such as wound healing, bone regeneration, and more.
The team used a low-power laser to trigger human dental stem cells to form dentin, the hard tissue that
Chemotherapy saves lives, but it also kills healthy tissue like bone marrow. According to a new study involving three patients with glioblastoma, a deadly cancer of the brain, stem cells from cancer patients’ own blood may protect their bone marrow from the toxic effects of treatment.
Glioblastomas often carry an active form of a gene called MGMT, which is a DNA repair enzyme that protects the cancer cells against chemotherapy. To overcome that protective effect, doctors use benzylguanine, a drug that blocks MGMT – but that drug also makes bone marrow and blood cells vulnerable. For this study, scientists at Fred Hutchinson
Muscle wasting linked to old age might one day be treated using stem cells, claim US scientists.
A University of Colorado team transplanted cells into mice and saw the muscle more than double in size – staying that way even into old age.
They say their work, reported in Science Translational Medicine, may have promise in treating muscle-wasting conditions such as muscular dystrophy.
A UK expert said producing a human treatment might be difficult.
Stem cells are cells found in the body which can divide and become a variety of different types of tissue.
Scientists believe they could potentially help treat a large number
Verastem Inc, focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that a paper, entitled “Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship,” has been published by Verastem scientists in the latest issue of the journal Science Translational Medicine.
The paper describes the finding that loss of the tumor suppressor merlin predicts for increased responsiveness to drugs targeting cancer stem cells through inhibition of focal adhesion kinase (FAK). Since merlin loss is particularly prevalent in mesothelioma (approximately 50% of patients), the efficacy of FAK inhibition was demonstrated in several
Stem cell therapy represents a promising strategy in regenerative medicine. However, cells need to be carefully preserved and processed before usage. In addition, cell transplantation carries immunogenicity and/or tumourigenicity risks.
Mounting lines of evidence indicate that stem cells exert their beneficial effects mainly through secretion (of regenerative factors) and membrane-based cell–cell interaction with the injured cells. Here, we fabricate a synthetic cell-mimicking microparticle (CMMP) that recapitulates stem cell functions in tissue repair.
CMMPs carry similar secreted proteins and membranes as genuine cardiac stem cells do. In a mouse model of myocardial infarction, injection of CMMPs leads to the preservation of viable